Monitoring heart disease patients via WhatsApp during the COVID-19 pandemic

Phase 2

• Conditions: COVID-19

• Registration Number: RBR-5q6x56k
• Lead Sponsor: Hospital Geral Roberto Santos

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-12-01
• Study Start: 2022-03-28
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients were eligible for inclusion if they were 18 years of age or older, had heart failure with an ejection fraction less than or equal to 40%, regardless of etiology, assessed by an echocardiogram performed within a maximum of six months before randomization, functional class I- III (New York Heart Association), optimized drug therapy, cell phone with access to the Whatsapp® application.

Exclusion Criteria

Patients with any non-cardiac condition that, in the investigator's opinion, leads to a life expectancy of less than 12 months, functional class IV (NYHA), cardiogenic shock, cardiac surgery within the previous 8 weeks, heart transplant waiting list, failure chronic kidney disease, uncontrolled high blood pressure, inability to understand or interact with text messages due to illiteracy, cognitive impairment or social problems, severe depression and uncontrolled arrhythmia.

Study & Design

• Study Type: Intervention
• Study Design: Not specified